Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. - Wikidata - wikimedia - TriplyDB

Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.

Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.

http://www.wikidata.org/entity/Q43770922

about

Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapy A Practical Approach to Management of Chronic Hepatitis B Natural History and Clinical Consequences of Hepatitis B Virus Infection Management of patients with hepatitis B who require immunosuppressive therapy Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation Evolution of hepatitis B management in kidney transplantation Antiviral treatment for chronic hepatitis B in renal transplant patients Efficacy and tolerability of lamivudine in hepatitis B infected renal transplant recipients: A single center study.Hepatitis B and Renal Disease.Rapid quantification of hepatitis B virus DNA by real-time PCR using efficient TaqMan probe and extraction of virus DNA.Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patients Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis.Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States Asian-Pacific consensus statement on the management of chronic hepatitis B: an update.Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation.Infections in hemodialysis: a concise review. Part II: blood transmitted viral infections Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients.Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable.Management of chronic hepatitis B virus infection: a new era of disease control.Prophylaxis of hepatitis B infection in solid organ transplant recipients.Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy.Hepatitis B virus infection and renal transplantation Chronic viral hepatitis in kidney transplantation.Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.Post-transplant withdrawal of lamivudine results in fatal hepatitis flares in kidney transplant recipients, under immune suppression, with inactive hepatitis B infection.Use of telbivudine in kidney transplant recipients with chronic hepatitis B virus infection: A preliminary experience.Implementation of an in-house quantitative real-time polymerase chain reaction method for Hepatitis B virus quantification in West African countries.High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.Hepatitis B in renal transplant patients.Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.Entecavir treatment in kidney transplant recipients infected with hepatitis B.Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B.Impact of posttransplantation glomerulonephritis on long-term outcome of kidney transplants: single-center 20-year experience.Lamivudine therapy for hepatitis B infection in post-renal transplant patients: results after 36 months follow-up.Double-blinded placebo-controlled study of Phyllanthus urinaris for the treatment of chronic hepatitis B.Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies.Prospective study on lamivudine-resistant hepatitis B in renal allograft recipients.

P2860

Q24240881-512F1A54-065A-4843-BF7E-EA5BD16030B0 Q24810145-169C29BD-8C9B-402F-9EB3-91C90E842214 Q24810151-81C2FB10-8C2C-419F-9573-450695AF8DDF Q26853490-F660FA55-6C33-4373-A9B8-6262D7B7D6D8 Q26864647-2D85FF7F-DA5D-4809-924D-65B92A554391 Q26995706-8001315F-FB76-4803-94CC-3022D1451322 Q28084189-81BDDA19-F60A-4090-9DC7-CB8DD304166B Q33809854-9FC59101-7BE5-4718-90F2-C0CB9B928D69 Q33819104-D9ABC71E-11DA-41D1-98E9-513C7E5E65DA Q33866530-2E509503-6C6C-4EF9-BC5A-98275BBFE421 Q34168451-0C2A5DA4-37CD-4DBE-B1AF-B26E42AC3636 Q34734311-9F6933DA-7376-401E-8201-D9CCD541D7C6 Q35030670-54FFDB04-11D0-4701-957E-40DC615589C9 Q35072182-C2509C7E-52BC-4B48-8272-DABF98CBDD1A Q35210407-26507F45-D492-4D6A-8A0B-980623B4D576 Q35532440-7FB248C5-1EB5-44A2-97A1-5A65D5F968C9 Q35637506-A58BB467-2487-4599-A568-BFEF5E2CD0F8 Q36135493-3303FF9D-D785-400C-8B21-0E10404BB028 Q36254143-B98A733A-C631-4E6E-8FC8-1780B4A9ED60 Q36311839-DA853555-9685-43BE-B4ED-EFDCBC7531A0 Q36393856-94CEEB58-4D2B-404F-A35F-B54A93CE048B Q36886518-2D9C093F-C957-4349-9206-2319FD2AFF4A Q37001173-732AB35E-0828-4E50-864B-1E365807362D Q37780176-EACD3473-9D24-4305-B94B-6FD6FB1E16AF Q37833898-603078D5-D6DD-4252-9664-CB9C69113E9B Q38168296-82C078D8-F3A7-41A2-83E4-B2D9B37D6E76 Q40211892-B79D7769-DC8E-4F3E-88C5-48FA01227324 Q40410635-5C7CE685-7FE5-423D-B7F1-39C43649F028 Q40471393-7D40BD65-FB2B-4D44-B8EE-0F889C6E1937 Q41152880-E48BD59E-874D-472A-A55B-7F866F3A7F4C Q41690591-B880ED11-6018-4A3A-B197-8D0605AC1540 Q42153911-76C3FB41-B451-4C2C-9829-0AEAB3539030 Q42209408-E9882093-7B99-4F13-81F8-AAF839287EB3 Q42231500-B0E0CA74-F77F-4E40-9A0F-EB2C3B3C902F Q43275846-C6CB652A-072E-40D9-861C-FB10ECA47413 Q43492328-9BB5075F-7EC2-444E-90ED-DA614BF539D8 Q43886978-ABC98D8C-07AD-4B32-BBE6-1747D562714A Q44535161-E6E532ED-607C-48C2-8C97-B484E8308EF5 Q44783623-CBAA48A9-806A-4ADD-93AC-E61562A98ECA Q44935463-5AD2D034-1709-4F19-A5A9-5EA595D4A7EA

P2860

Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.

http://www.wikidata.org/entity/Q43770922

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Preemptive lamivudine therapy ...... e kidney allograft recipients.

@en

Preemptive lamivudine therapy ...... e kidney allograft recipients.

@nl

type

label

Preemptive lamivudine therapy ...... e kidney allograft recipients.

@en

Preemptive lamivudine therapy ...... e kidney allograft recipients.

@nl

prefLabel

Preemptive lamivudine therapy ...... e kidney allograft recipients.

@en

Preemptive lamivudine therapy ...... e kidney allograft recipients.

@nl

P1433

Q43770922-57B20734-2BE5-4701-8E7D-CAB4989926FD

P1476

Q43770922-6BD4697A-65A1-439A-92AB-E4057D42303C

P2093

Q43770922-2E9F960C-36AF-42BF-976B-259CDE629BBD

Q43770922-7FD9581C-8118-4B82-8C14-F88B5FF2038E

Q43770922-82A7C646-7503-4A37-AB17-EB892D1927CE

Q43770922-9695D4AF-9A35-4D58-8A7C-37F4570BF6C0

Q43770922-9FE4FAC4-EEE1-475D-9979-BE7F9ED374FC

Q43770922-C98BB7AC-9F21-49E3-873F-733A54FB7ECC

P304

Q43770922-D45E3641-1790-4925-B0E4-17B63BD9446C

P31

Q43770922-2527623B-196E-4058-98C9-DB5583ED9033

P356

Q43770922-E3EF39F2-C56A-401E-B4B2-2B0E891B663E

P407

Q43770922-8E435022-1A71-4A53-9CE1-7BA352B953EB

P433

Q43770922-EF278BBB-42CA-4013-9B00-B7B5CB98829B

P478

Q43770922-DF0578A9-71ED-4B57-88F7-A42BE37B49B3

P577

Q43770922-F27CAF43-BD81-4417-B001-468408CEF562

P5875

Q43770922-FE07C2DC-727F-4B9F-BFDB-97B766FFBAAD

P698

Q43770922-8A711C52-EE00-486F-AD0D-101908B364D4

P356

JHEP.2002.36156

P1433

P1476

Preemptive lamivudine therapy ...... e kidney allograft recipients.

@en

P2093

Colin S o Tang

http://www.w3.org/2001/XMLSchema#string

Guo Xiang Fang

http://www.w3.org/2001/XMLSchema#string

Ignatius K p Cheng

http://www.w3.org/2001/XMLSchema#string

Kar Neng Lai

http://www.w3.org/2001/XMLSchema#string

Stephen K n Ho

http://www.w3.org/2001/XMLSchema#string

Tak Mao Chan

http://www.w3.org/2001/XMLSchema#string

P304

1246-1252

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/JHEP.2002.36156

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11068417

http://www.w3.org/2001/XMLSchema#string

P698

12395336

http://www.w3.org/2001/XMLSchema#string